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ABSTRACT
Objective: This study was conducted to determine the adherence of medications among type 2 diabetes mellitus (DM) patients. To evaluate adherence 
to therapy and study factors associated with non-adherence and adherence in patients with type II DM.
Methods: A cross-sectional, observational study was conducted for 6 months in three hospitals. A total of 200 type II diabetic patients, who were 
on anti-diabetic drug therapy for at least 6 months, were enrolled. Blood glucose was measured and details of drug therapy were noted. Medication 
adherence was assessed using the Morisky Medication Adherence Scale and adherence scores were calculated.
Results: Only 15% had high medication adherence, while 24% had moderate and 61% had low medication adherence. Only 30% were having 
optimally controlled glycemic levels, whereas 70% were having uncontrolled glycemic levels. Medication adherence scores were lower (reflecting 
lower adherence) in type II patients with uncontrolled glycemic levels than those having optimally controlled glycemic levels, but this difference was 
not statistically significant.
Conclusion: Overall, medication adherence was low in type II diabetic patients. The study shows that to improve medication adherence, better 
counseling and health education of patients are required. Although several patients were adherent to therapy, adherent patients are more preferably 
to achieve glycemic control than nonadherent patients. Greater efforts are needed to facilitate diabetes self-management behaviors to improve patient 
outcomes.
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INTRODUCTION
Diabetes mellitus (DM) is a chronic metabolic disorder characterized 
by the presence of hyperglycemia accompanied by impairment in the 
metabolism of carbohydrates, lipids, and proteins. DM can vary greatly, 
but always include defects in either secretion of insulin or response or 
both at some point in the course of the disease. Most patients with DM 
have either Type 1 DM (which is immune-mediated or idiopathic) or 
Type 2 DM (non-insulin dependent DM) is the most widely recognized 
type of DM characterized by insulin resistance, hyperglycemia, and 
relative insulin deficiency. Type 2 DM results from the collaboration 
between genetic, environmental and behavioral risk factors [1]. DM 
is a growing public health problem worldwide with an estimated 
177 million individuals affected in 2003, 221 million by 2010 and is 
expected to rise to 300 million in 2025 with the highest increases in 
Asia and Africa [2]. By 2025, it is assessed over 75% of individuals 
with diabetes are accounted in low-income countries. The use of 
medication plays a key role in the management of T2DM. However, 
the effectiveness of the treatment for diabetes relies upon the degree 
of medication adherence towards the endorsed treatment. As per the 
World Health Organization (WHO), guideline adherence is up to, which 
degree an individual behavior; following a diet, receiving medication, 
and executing lifestyle changes corresponds with recommendations 
from the health care provider [3]. Non-adherence to medication is 
most basic among patients with diabetes [4]. Inadequate adherence 
compromises safety and prompts ineffective treatment, which ascends 
in mortality and morbidity rate. Medication adherence is essential for 
successful treatment in patients with DM results in a better outcome, 
for example, hemoglobin A1C values, reduces the risk of hospitalization 
and mortality as well as the health care costs will be diminished [5]. 
Medication adherence to anti-diabetics were estimated using the 
Morisky Medication Adherence Scale (MMAS-8). Endorsement to utilize 
and interpret the (MMAS-8) into any languages like English, Hindi, 
and Urdu or any other language that comprehended by the patients 
was obtained by the developers. The interpretation was carried 
out according to the standard backward and forward method. The 
(MMAS-8©) comprises of eight inquiries intended to assess medication 
adherence. The initial 7 are Yes/No inquiries while the last question is 
replied with a 5-point Likert scale. One point each is given in a sentence 
dependent on the appropriate response. In the initial 7 questions, one 
point is given for each “NO” answer except question number 5 where 
one point is given for the “YES” answer. For thing number 8, one point 
is given for “never/rarely” in a while and zero points are given for all 
the time. The complete MMAS-8© score is the summation of the scores 
for the 8 questions. The all-out MMAS-8© score is the summation of the 
scores for the 8 questions. The full-scale score got ranged from 0 to 8. 
In this assessment, patients with a full-scale score of MMAS-8© <6 were 
considered nonadherent.
Estimation of medication adherence rates to anti-diabetic revealed 
variable results, but indicated a strong tendency toward poor medication 
adherence [6,7]. The medication adherence to oral anti-diabetics were 
defined according to the WHO ATC Classification System, including the 
defined daily dose classification, and finally provided by the proportion 
of days covered (PDC) with an observation period of 12 months. In the 
literature, the PDC in the recommended measure that provided rather 
conservative, but precise estimates and was calculated as follows: 
the number of days of oral antidiabetic medication supplied between 
the first prescription (defined as index date) and the last date of the 
1-year perception period following the index date was isolated by the 
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total days of the interval (365 days) for every patient. The defined daily 
doses for diabetes drug classes recommended by the WHO were used to 




Participants were recruited from three public health hospitals in South 
India for 6 months (i.e., July-December). These hospitals were specifically 
chosen because they differ in terms of the characteristics of the patients 
they serve and the geographical regions in which they are situated. The 
variability of the sites provided a broad range of patients with DM.
Study respondents and data collection
This was a cross-sectional and observational study to evaluate DM, 
diabetes with other commodities, diabetes-related knowledge, 
demographic and clinical factors with medication adherence among 
patients with DM using the MMAS-8. The approach we followed 
in this study was similar to that used by other scholars who 
investigated the relationship between medication adherence and 
other factors [8-11]. The present research approach was based on 
using medication adherence as an outcome while using demographic, 
clinical, psychological factors, antidiabetic therapy, glycemic status 
as independent variables. The tools used in this study have been 
previously used by other investigators [8-15]. The study included 
a convenience sample of the adult population. Participants were 
recruited from three hospitals, while waiting to be seen by their health 
care providers. A sample of 200 diabetic patients who reported as 
type 1 and 2 diabetes, availability of a medical record at the diabetic 
clinic; a history of at least 1 year of DM; currently being under medical 
care for diabetes; and finally willingness to participate in this study are 
included in the study. Patients with physical and/or mental conditions 
that could interfere with the participant’s ability to understand and/
or answer questions in any of the scales used were excluded. Diabetes-
related knowledge has also been reported to influence both medication 
adherence and glycemic control [18].
Statistical methods
Data recorded were entered in Microsoft Excel version 2018. Data 
were expressed in actual numbers, mean ± standard deviation, 
and percentage; t-test was used to compare the mean between the 
two groups. The probability p<0.05 was considered as statistically 
significant.
RESULTS
A total of 200 type II diabetic patients was included and analyzed. The 
mean age of the sample, a male was 58.8 (±10) (range = 35–86) years. 
Most of the participants were females 126 (63%). Patients reported 
an average of (130; 65%)of additional illnesses. Hypertension (155; 
77.5%), hypothyroidism (17; 8.5%), coronary artery disease (CAD) 
179
Asian J Pharm Clin Res, Vol 12, Issue 10, 2019, 177-180
 Rani et al. 
(34; 17%) and stroke (25; 12.5%) were the most frequently reported 
additional illnesses in the study sample. Patients reported an average 
of 44 (22%) of Monotherapy and 156 (78%) of combination therapy 
of anti-diabetic medications and 2.3±0.9 different medications taken 
daily and taking ≥4 medications regularly. The mean duration of DM 
reported by the patients was 9.5±21.4 years. The mean duration of 
glycemic status, the controlled level is 60 (30%) and the uncontrolled 
level is 140 (70%) was reported by the patients. The mean of insulin 
use to controlled the glycemic level was 135 (67.5%) reported by the 
patients and the mean of glucose random blood sugar (GRBs) reported 
by the patients was 286.7. The demographic data along with details 
of the duration of treatment, current anti-diabetic drug therapy, and 
medication adherence were recorded. Their GRBs was measured by 
Accucheck active Glucometer. Demographic and clinical characteristics 
of participants are presented in (Table 1).
Adherence to ant diabetic medication
A total study of 200 diabetic patients only 15% were adherent to the 
anti-diabetic medication while 24% had moderate and 61% had low 
medication adherence based on the total MMAS score presented in 
(Table 2).
Reported adherence and beliefs
As the study was conducted in 200 patients only a few of them 
were highly adherent and most of them said that they forgot to take 
medicines when away from home and/or traveling of about (56%); 81% 
complained of inconvenience and difficulty in adhering to medication 
plan; 67% said they just forget to take medicines.
Antidiabetic medication adherence between diabetics, according 
to controlled and uncontrolled glycemic levels
We found that only 30% were having controlled blood glucose, whereas 
70% were having uncontrolled blood glucose despite being on drug 
therapy. On subgroup analysis, the MMAS score was higher in the 
controlled group in comparison with the uncontrolled group, but this 
difference was not statistically significant (Table 3).
DISCUSSION
The findings of the study suggest that medication adherence was low 
and addresses the issue of non-adherence-among type II diabetic 
patients. Worldwide studies using various research assessment 
instruments and systematic reviews have addressed issues of poor 
medication adherence among diabetes patients.
In this study, medication adherence was assessed by using MMAS-8 
a validated scale. The scale is designed to facilitate the identification 
of barriers and behaviors associated with adherence to medication. 
Only 15% had high medication adherence while 24% had moderate 
and 61% had low medication adherence. It was observed that many 
patients forgot to take medicines with them while traveling. Some of 
them stopped to take medicines on their own because they believed 
that their diabetes was under control. Others felt it was difficult to 
stick to a prescribed treatment plan and stopped to take medication. 
Hypertension (77.5%), CAD (34; 17%) and stroke (25; 12.5%) are the 
most frequent comorbidities recorded in the study. Most of them were 
in the combination therapy (78%) study in Study in south Nigeria show 
that 70.3% of the patients were on combination therapy and it was 
reflected the necessity of intensive control of blood glucose level [16]. 
The findings are comparable to several Indian studies documented 
poor adherence to antidiabetic medication. Ahmad et al. observed 
that Adherence to medications in type 2 DM was unsatisfactory and 
resulted in wastage of medications and less than the optimal outcomes. 
The determinants of medication nonadherence were age, medication 
information scores, and the nearness of comorbidities. The recognized 
degree of adherence in this study was like past investigation findings. 
In this study poor Medication adherence among the type 2 DM patients 
was observed, which has to be improved for the better therapeutic 
outcome. The medication knowledge should be improved mostly 
in patients with comorbidities [17]. One of the biggest challenges 
for health care providers today is addressing the continued needs 
and demands of individuals with chronic illnesses like diabetes [19]. 
The importance of regular follow-up of diabetic patients with the 
health care provider is of great significance in averting any long term 
complications. Studies have reported that strict metabolic control can 
delay or prevent the progression of complications associated with 
diabetes [20]. Results of huge randomized trials including patients 
with type 1 diabetes or recently recognized or set up type 2 diabetes 
demonstrate that control of glycemia delays the onset and slows the 
progression of microvascular complications, including nephropathy, 
retinopathy, and neuropathy [21]. About 25% of patients with type 2 
DM as of now have microvascular complications at the time of diagnosis 
recommending that they have had the disease for over 5 years at the 
time of diagnosis [22]. Some of the Indian studies revealed very poor 
adherence to treatment regimens due to poor attitude towards the 
disease and poor health literacy among the general public [23]. In a few 
studies, it has been concluded that structured education to patients by 
a pharmacist by applying pharmaceutical care activities has shown a 
significant improvement in medication adherence behavior, supporting 
the interventional educational role of the pharmacist [24]. To improve 
medication adherence as we should assure that patients achieve 
continuing education about the disease and medications, provide the 
Table 1: Sociodemographic characteristics of respondents
Patient characteristics Value
Patients with type II diabetics 200






Duration of treatment in years (mean) 9.5±21.4
Number of medications (mean) 2.3±0.9











Presence of chronic disease (%)
Yes 130 (65)
No 70 (35)
n=200, GRBs: Glucose random blood sugar
Table 2: Level of medication adherence among type II diabetic 
patients
Medication adherence level (as per MMAS) Percentage n=200
Low adherence (score >2) 61 (122)
Moderate adherence (score 1 or 2) 24 (48)
High adherence (score 0) 15 (30)
MMAS: Morisky Medication Adherence Scale 1
Table 3: Comparison of medication adherence score between 
diabetic patients with controlled and uncontrolled glycemic 
levels






*p-value between-group comparisons by in 1. SD: Standard deviation
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patient with written and oral information, and encouraging patients to 
visit their health care providers regularly [25].
CONCLUSION
Our findings showed that medication adherence was low in type II 
diabetic patients. As the current prescribing plan resulted in glycemic 
control in less than half of the patients, the majority are still not 
meeting the recommended blood glucose target. This is mainly due 
to poor medication adherence with prescribed therapy and poor 
knowledge and practice of self-management behaviors. There is a need 
for regular monitoring of patient adherence to medication and initiate 
steps to improve the adherence to antidiabetic medication. Therefore, 
counseling and health education of the patients related to medication 
adherence and strategies to increase drug availability need to be 
improved. Finally, improving knowledge of diabetic patients about their 
illness and self-management will positively influence their medication 
adherence and therapeutic outcome.
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